ClinicalTrials.gg
Not yet recruitingNCT07758127HER2Updated Aug 12, 2026

Updates and Insights on HER2 in Breast Cancer in Sohag Governorate

An observational study in HER2 Status in Breast Cancer, sponsored by Sohag University. Not yet recruiting at 1 site in Egypt. Open to female participants aged 26 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-08-12.

Sponsored by Sohag University · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
100
Ages
26 Years to 85 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 19 studies in Breast Neoplasms by Sohag University — 12 open to participants now, 13 under way, none of them phase 3. Breast Neoplasms · Sohag University.

Planned enrollment
3rd of 14
100 · median 100
Started
2026
with 3 others
Observational
14 of 19
10 open now
Primary completion
2027-09
later than 12 of 12 live
Registered
18th of 19
by date

Among the 19 studies in Breast Neoplasms by Sohag University, this one is the 3rd largest by planned enrollment of the 14 observational ones that give a count, is one of 4 that started in 2026, is one of 14 observational ones, reaches primary completion later than 12 of the 12 other live ones, and was the 18th registered.

Breast Neoplasms

14,843 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

12 of the 19 studies in Breast Neoplasms by Sohag University are open now, in 1 country. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 12 open studies →

Where they have run

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,573 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 26 Years to 85 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Breast Neoplasms by Sohag University, or all of them as a file.
02

Study summary

  • To evaluate HER2 expression in breast carcinoma with emphasizing HER2-ultralow, and HER2-low, HER2 equivocal tumors.
  • To correlate the results of HER2 with clinico-pathological prognostic parameters; examples tumor grade, Ki-67 proliferation index, nodal status, tumor size, lympho-vascular invasion, and perineural invasion, tumor infiltrating lymphocytes
  • To access interobserval agreement in HER2 score interpretation
Read the detailed description

HER2 status is no longer simply classified as a positive or negative. It is now evaluated on a score from 0 to 3+, where score 3+ indicates HER2-positive disease because it shows strong, complete circumferential membranous staining. In the HER2-negative spectrum, score 1+ and score 2+ without gene amplification are classified as HER2-low, while score 0 involves both HER2-null cases with no membrane staining and HER2-ultralow cases with faint or weak incomplete membranous staining in ≤10%, of tumor cells. In addition, ISH can be used to determine HER2 gene amplification status. The emergence of HER2-low and also HER2-ultralow concepts has challenged the traditional binary framework and increased the need for collective reporting. As a result, careful interpretation of delicate staining patterns, reproducible scoring and appropriate use of complementary testing methods are now central to accurate HER2 classification in both primary and metastatic breast cancer.

03

Conditions studied

  • HER2 Status in Breast Cancer

Browse trials for

Keywords

  • HER2
04

Who can participate

Ages eligible
26 Years to 85 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population includes female patients with histopathologically confirmed breast cancer diagnosed at Sohag Oncology center during the study period (2025-2026). Archived formalin-fixed paraffin-embedded tissue blocks and corresponding pathology records will be retrospectively reviewed to evaluate HER2 status. Only cases meeting the eligibility criteria will be included.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Breast cancer cases diagnosed during 2025 and 2026.
  • Cases with available immunohistochemical results.
  • Cases with sufficient tissue material for evaluation.
  • Cases with complete clinical and follow-up data.
  • Cases that were accessible for pathologic review

Exclusion criteria

Exclusion Criteria:

  • Cases with insufficient, destroyed, necrotic, or unavailable tissue blocks.
  • Cases with incomplete clinical information.
  • Cases lacking adequate immunohistochemical assessment.
  • Cases outside the study period
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
100 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Breast cancer female patients

    Female patients with histopathologically confirmed breast cancer diagnosed at Sohag Oncology center during 2025-2026. Archived formalin-fixed paraffin-embedded tissue samples and pathology records will be retrospectively reviewed to evaluate HER2 status by immunohistochemistry (IHC)

06

What researchers measure

Primary outcomes

  1. HER2 status in breast cancer

    To evaluate the HER2 status among breast cancer patients diagnosed at Sohag Oncology center using immunohistochemistry (IHC) and, when indicated, in situ hybridization (ISH), and to describe the distribution of HER2 expression.

    Time frame: 2025/2026

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2026; primary completion for Sep 2027, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 5, 2026
First posted
Aug 11, 2026
StartEst.
Sep 2026
Primary completionEst.
Sep 2027
CompletionEst.
Dec 2027
Last update
Aug 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07758127
Lead sponsor
Sohag University
Collaborators
Sohag Oncology Center
Responsible party
Rana Amgad Anwar (Pathology resident at Sohag Oncology Center, Sohag University) — Principal investigator
First posted
Aug 11, 2026
Start date
Sep 2026 (estimated)
Primary completion
Sep 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Aug 12, 2026

Study contacts

Dr. Fatma El-Zahraa Prof. Dr. Fatma El-Zahraa Salah El-Deen Safe El-Deen, Professor of Pathology
Contact
fatmafm2002@yahoo.com
01007970144
Dr. Ola Dr. Ola Mohamed Nageeb Mazeed, Lecturer of Pathology
Contact
Olaamohamed@med.sohag.edu.eg
01005156672

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion